{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:27:55Z","timestamp":1792693675233,"version":"4.5.0"},"reference-count":138,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Inherited retinal diseases (IRDs) are a clinically and genetically diverse group of progressive degenerative disorders that can result in severe visual impairment or complete blindness. Despite their predominantly monogenic inheritance patterns, the genetic complexity of over 300 identified disease-causing genes presents a significant challenge in correlating clinical phenotypes with genotypes. Achieving a molecular diagnosis is crucial for providing patients with definitive diagnostic clarity and facilitating access to emerging gene-based therapies and ongoing clinical trials. Recent advances in next-generation sequencing technologies have markedly enhanced our ability to identify genes and genetic defects leading to IRDs, thereby propelling the development of gene-based therapies. The clinical success of voretigene neparvovec (Luxturna), the first approved retinal gene therapy for RPE65-associated Leber congenital amaurosis (LCA), has spurred considerable research and development in gene-based therapies, highlighting the importance of reviewing the current status of gene therapy for IRDs, particularly those utilizing adeno-associated virus (AAV)-based therapies. As novel disease-causing mutations continue to be discovered and more targeted gene therapies are developed, integrating these treatment opportunities into the standard care for IRD patients becomes increasingly critical. This review provides an update on the diverse phenotypic\u2013genotypic landscape of IRDs, with a specific focus on recent advances in the understanding of IRDs in children with infantile nystagmus syndrome (INS). We highlight the complexities of the genotypic\u2013phenotypic landscape of INS-associated IRDs, including conditions such as achromatopsia, LCA, congenital stationary night blindness, and subtypes of retinitis pigmentosa. Additionally, we provide an updated overview of AAV-based gene therapies for these diseases and discuss the potential of gene-based therapies for underlying IRDs that lead to INS, offering a valuable resource for pediatric patients potentially eligible for ongoing clinical trials.<\/jats:p>","DOI":"10.3390\/life14111356","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T09:07:04Z","timestamp":1729674424000},"page":"1356","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Infantile Nystagmus Syndrome\u2014Associated Inherited Retinal Diseases: Perspectives from Gene Therapy Clinical Trials"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8687-0763","authenticated-orcid":false,"given":"Xiaoming","family":"Gong","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Akron Children\u2019s Hospital, Akron, OH 44308, USA"},{"name":"Vision Center of Excellence, Rebecca D. Considine Research Institute, Akron Children\u2019s Hospital, Akron, OH 44308, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Hertle","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Akron Children\u2019s Hospital, Akron, OH 44308, USA"},{"name":"Vision Center of Excellence, Rebecca D. Considine Research Institute, Akron Children\u2019s Hospital, Akron, OH 44308, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jcjo.2015.07.010","article-title":"Infantile nystagmus syndrome: Clinical characteristics, current theories of pathogenesis, diagnosis, and management","volume":"50","author":"Richards","year":"2015","journal-title":"Can. J. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1167\/iovs.09-3486","article-title":"The prevalence of nystagmus: The Leicestershire nystagmus survey","volume":"50","author":"Sarvananthan","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ajo.2017.07.006","article-title":"Incidence and Types of Pediatric Nystagmus","volume":"182","author":"Nash","year":"2017","journal-title":"Am. J. Ophthalmol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.pedneo.2014.02.007","article-title":"Nystagmus in childhood","volume":"55","author":"Papageorgiou","year":"2014","journal-title":"Pediatr. Neonatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/13816810.2016.1266667","article-title":"The clinical evaluation of infantile nystagmus: What to do first and why","volume":"38","author":"Bertsch","year":"2017","journal-title":"Ophthalmic Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0161-6420(89)32864-8","article-title":"Visual sensory disorders in congenital nystagmus","volume":"96","author":"Weiss","year":"1989","journal-title":"Ophthalmology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/jamaophthalmol.2017.4859","article-title":"Accuracy of Next-Generation Sequencing for Molecular Diagnosis in Patients With Infantile Nystagmus Syndrome","volume":"135","author":"Rim","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00055735-200010000-00007","article-title":"Nystagmus","volume":"11","author":"Gottlob","year":"2000","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jaapos.2023.07.007","article-title":"Genetic testing for infantile nystagmus syndrome with or without associated findings","volume":"27","author":"Cavuoto","year":"2023","journal-title":"J. Am. Assoc. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jamaophthalmol.2013.5833","article-title":"A unifying neurologic mechanism for infantile nystagmus","volume":"132","author":"Brodsky","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/2576117X.2022.2064190","article-title":"A Story of Discovery and Change: What We Learned from Studying Nystagmus in Infancy and Childhood","volume":"72","author":"Hertle","year":"2022","journal-title":"J. Binocul. Vis. Ocul. Motil."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1167\/tvst.7.4.6","article-title":"Inherited Retinal Degenerations: Current Landscape and Knowledge Gaps","volume":"7","author":"Duncan","year":"2018","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.preteyeres.2010.03.004","article-title":"The molecular basis of human retinal and vitreoretinal diseases","volume":"29","author":"Berger","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2633004021998714","DOI":"10.1177\/2633004021998714","article-title":"Novel therapeutics in nystagmus: What has the genetics taught us so far?","volume":"2","author":"Self","year":"2021","journal-title":"Ther. Adv. Rare Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2017.10.004","article-title":"Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives","volume":"63","author":"Dias","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Moon, D., Park, H.W., Surl, D., Won, D., Lee, S.T., Shin, S., Choi, J.R., and Han, J. (2021). Precision Medicine through Next-Generation Sequencing in Inherited Eye Diseases in a Korean Cohort. Genes, 13.","DOI":"10.3390\/genes13010027"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"0291","DOI":"10.34133\/research.0291","article-title":"AAV for Gene Therapy in Ocular Diseases: Progress and Prospects","volume":"6","author":"He","year":"2023","journal-title":"Research"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Zhou, R., and Caspi, R.R. (2010). Ocular immune privilege. F1000 Biol. Rep., 2.","DOI":"10.3410\/B2-3"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2147\/OPTH.S364200","article-title":"Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses","volume":"16","author":"Ghoraba","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/TACG.S383453","article-title":"Adeno-Associated Virus (AAV)\u2014Based Gene Therapies for Retinal Diseases: Where are We?","volume":"16","author":"Ail","year":"2023","journal-title":"Appl. Clin. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ajhg.2016.12.003","article-title":"Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease","volume":"100","author":"Carss","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/13816810490514261","article-title":"Leber congenital amaurosis: A genetic paradigm","volume":"25","author":"Allikmets","year":"2004","journal-title":"Ophthalmic Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/08820530701745215","article-title":"Leber congenital amaurosis: Disease, genetics and therapy","volume":"23","author":"Ahmed","year":"2008","journal-title":"Semin. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.survophthal.2004.04.003","article-title":"An overview of Leber congenital amaurosis: A model to understand human retinal development","volume":"49","author":"Koenekoop","year":"2004","journal-title":"Surv. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/bjophthalmol-2016-309975","article-title":"Leber congenital amaurosis\/early-onset severe retinal dystrophy: Clinical features, molecular genetics and therapeutic interventions","volume":"101","author":"Kumaran","year":"2017","journal-title":"Br. J. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"107834","DOI":"10.1016\/j.exer.2019.107834","article-title":"Leber congenital amaurosis: Current genetic basis, scope for genetic testing and personalized medicine","volume":"189","author":"Kondkar","year":"2019","journal-title":"Exp. Eye Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"a017350","DOI":"10.1101\/cshperspect.a017350","article-title":"Leber congenital amaurosis caused by mutations in GUCY2D","volume":"5","author":"Boye","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.preteyeres.2017.10.003","article-title":"Genotype-functional-phenotype correlations in photoreceptor guanylate cyclase (GC-E) encoded by GUCY2D","volume":"63","author":"Sharon","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ajo.2019.10.019","article-title":"GUCY2D-Associated Leber Congenital Amaurosis: A Retrospective Natural History Study in Preparation for Trials of Novel Therapies","volume":"210","author":"Bouzia","year":"2020","journal-title":"Am. J. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1086\/507318","article-title":"Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis","volume":"79","author":"Koenekoop","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/IAE.0000000000003133","article-title":"Leber congenital amaurosis due to cep290 mutations\u2014Severe vision impairment with a high unmet medical need: A Review","volume":"41","author":"Leroy","year":"2021","journal-title":"Retina"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.ophtha.2017.12.013","article-title":"Leber Congenital Amaurosis Associated with Mutations in CEP290, Clinical Phenotype, and Natural History in Preparation for Trials of Novel Therapies","volume":"125","author":"Sheck","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ajo.2022.09.002","article-title":"CRB1-Associated Retinal Dystrophies: Genetics, Clinical Characteristics, and Natural History","volume":"246","author":"Georgiou","year":"2023","journal-title":"Am. J. Ophthalmol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/08820538.2013.825277","article-title":"CRB1, one gene, many phenotypes","volume":"28","author":"Ehrenberg","year":"2013","journal-title":"Semin. Ophthalmol."},{"key":"ref_35","first-page":"1789","article-title":"Detailed clinical characterisation, unique features and natural history of autosomal recessive RDH12-associated retinal degeneration","volume":"103","author":"Fahim","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1080\/13816810.2020.1802763","article-title":"Macula-predominant retinopathy associated with biallelic variants in RDH12","volume":"41","author":"Arno","year":"2020","journal-title":"Ophthalmic Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/ng.2361","article-title":"NMNAT1 mutations cause Leber congenital amaurosis","volume":"44","author":"Falk","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/ng.2356","article-title":"Mutations in NMNAT1 cause Leber congenital amaurosis and identify a new disease pathway for retinal degeneration","volume":"44","author":"Koenekoop","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1076\/1381-6810(200009)2131-ZFT135","article-title":"Mutational analysis and clinical correlation in Leber congenital amaurosis","volume":"21","author":"Dharmaraj","year":"2000","journal-title":"Ophthalmic Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/bjophthalmol-2014-306505","article-title":"The cone dysfunction syndromes","volume":"100","author":"Aboshiha","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/13816810.2017.1418389","article-title":"Achromatopsia: Clinical features, molecular genetics, animal models and therapeutic options","volume":"39","author":"Hirji","year":"2018","journal-title":"Ophthalmic Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.ophtha.2009.03.053","article-title":"Genetic etiology and clinical consequences of complete and incomplete achromatopsia","volume":"116","author":"Thiadens","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2013.08.017","article-title":"Retinal structure and function in achromatopsia: Implications for gene therapy","volume":"121","author":"Sundaram","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1167\/iovs.14-14937","article-title":"A prospective longitudinal study of retinal structure and function in achromatopsia","volume":"55","author":"Aboshiha","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/ng.3319","article-title":"Mutations in the unfolded protein response regulator ATF6 cause the cone dysfunction disorder achromatopsia","volume":"47","author":"Kohl","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/sj.ejhg.5201269","article-title":"CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia","volume":"13","author":"Kohl","year":"2005","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/ICU.0000000000000189","article-title":"Achromatopsia: A review","volume":"26","author":"Remmer","year":"2015","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1172\/JCI96098","article-title":"Accessory heterozygous mutations in cone photoreceptor CNGA3 exacerbate CNG channel-associated retinopathy","volume":"128","author":"Burkard","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/jmg.39.9.656","article-title":"Mapping of a novel locus for achromatopsia (ACHM4) to 1p and identification of a germline mutation in the alpha subunit of cone transducin (GNAT2)","volume":"39","author":"Aligianis","year":"2002","journal-title":"J. Med. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ajhg.2009.06.016","article-title":"Homozygosity mapping reveals PDE6C mutations in patients with early-onset cone photoreceptor disorders","volume":"85","author":"Thiadens","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/bjo.2007.126342","article-title":"Nystagmus characteristics in congenital stationary night blindness (CSNB)","volume":"92","author":"Pieh","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-3-319-95046-4_13","article-title":"Congenital Stationary Night Blindness","volume":"1085","author":"Tsang","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.preteyeres.2014.09.001","article-title":"Congenital stationary night blindness: An analysis and update of genotype-phenotype correlations and pathogenic mechanisms","volume":"45","author":"Zeitz","year":"2015","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.preteyeres.2018.03.005","article-title":"Non-syndromic retinitis pigmentosa","volume":"66","author":"Verbakel","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-1-40","article-title":"Retinitis pigmentosa","volume":"1","author":"Hamel","year":"2006","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/ng0593-54","article-title":"Localization of an autosomal dominant retinitis pigmentosa gene to chromosome 7q","volume":"4","author":"Jordan","year":"1993","journal-title":"Nat. Genet."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1136\/bjophthalmol-2015-307698","article-title":"RPGR-associated retinopathy: Clinical features, molecular genetics, animal models and therapeutic options","volume":"100","author":"Tee","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1167\/iovs.63.6.15","article-title":"Axial Length Distributions in Patients With Genetically Confirmed Inherited Retinal Diseases","volume":"63","author":"Williams","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"100898","DOI":"10.1016\/j.preteyeres.2020.100898","article-title":"The X-linked retinopathies: Physiological insights, pathogenic mechanisms, phenotypic features and novel therapies","volume":"82","author":"Arno","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ophtha.2022.11.015","article-title":"RP2-Associated X-linked Retinopathy: Clinical Findings, Molecular Genetics, and Natural History","volume":"130","author":"Georgiou","year":"2023","journal-title":"Ophthalmology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/hmg\/ddp469","article-title":"Human retinopathy-associated ciliary protein retinitis pigmentosa GTPase regulator mediates cilia-dependent vertebrate development","volume":"19","author":"Ghosh","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/78182","article-title":"Mutational hot spot within a new RPGR exon in X-linked retinitis pigmentosa","volume":"25","author":"Vervoort","year":"2000","journal-title":"Nat. Genet."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/humu.20733","article-title":"The human retinitis pigmentosa GTPase regulator gene variant database","volume":"29","author":"Shu","year":"2008","journal-title":"Hum. Mutat."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exer.2015.06.007","article-title":"RPGR: Its role in photoreceptor physiology, human disease, and future therapies","volume":"138","author":"Megaw","year":"2015","journal-title":"Exp. Eye Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/humu.20417","article-title":"Comprehensive survey of mutations in RP2 and RPGR in patients affected with distinct retinal dystrophies: Genotype-phenotype correlations and impact on genetic counseling","volume":"28","author":"Pelletier","year":"2007","journal-title":"Hum. Mutat."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1097\/IAE.0000000000002125","article-title":"Clinical and genetic characteristics of male patients with RPGR-associated retinal dystrophies: A Long-Term Follow-up Study","volume":"39","author":"Talib","year":"2019","journal-title":"Retina"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Hadalin, V., Sustar, M., Volk, M., Maver, A., Sajovic, J., Jarc-Vidmar, M., Peterlin, B., Hawlina, M., and Fakin, A. (2021). Cone Dystrophy Associated with a Novel Variant in the Terminal Codon of the RPGR-ORF15. Genes., 12.","DOI":"10.3390\/genes12040499"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Yang, L., Yin, X., Feng, L., You, D., Wu, L., Chen, N., Li, A., Li, G., and Ma, Z. (2014). Novel mutations of RPGR in Chinese retinitis pigmentosa patients and the genotype-phenotype correlation. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085752"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1167\/iovs.61.14.36","article-title":"Spectrum of Disease Severity in Patients With X-Linked Retinitis Pigmentosa Due to RPGR Mutations","volume":"61","author":"Karali","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_70","first-page":"816","article-title":"Expression of X-linked retinoschisis protein RS1 in photoreceptor and bipolar cells","volume":"42","author":"Molday","year":"2001","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/jmg.2006.047340","article-title":"X-linked retinoschisis: An update","volume":"44","author":"Sikkink","year":"2007","journal-title":"J. Med. Genet."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/bjo.79.7.653","article-title":"Infantile presentation of X linked retinoschisis","volume":"79","author":"George","year":"1995","journal-title":"Br. J. Ophthalmol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/bjophthalmol-2017-310593","article-title":"Bullous X linked retinoschisis: Clinical features and prognosis","volume":"102","author":"Hinds","year":"2018","journal-title":"Br. J. Ophthalmol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/archopht.1987.01060040083038","article-title":"Psychophysical and electroretinographic findings in X-linked juvenile retinoschisis","volume":"105","author":"Peachey","year":"1987","journal-title":"Arch. Ophthalmol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/00006982-200507000-00012","article-title":"Fundus findings and longitudinal study of visual acuity loss in patients with X-linked retinoschisis","volume":"25","author":"Apushkin","year":"2005","journal-title":"Retina"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.drudis.2019.05.038","article-title":"Ocular gene therapies in clinical practice: Viral vectors and nonviral alternatives","volume":"24","author":"Bordet","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.gt.3302233","article-title":"Gene therapy progress and prospects: Recombinant adeno-associated virus (rAAV) vectors","volume":"11","author":"Flotte","year":"2004","journal-title":"Gene Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","article-title":"Adeno-associated virus serotypes: Vector toolkit for human gene therapy","volume":"14","author":"Wu","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Au, H.K.E., Isalan, M., and Mielcarek, M. (2021). Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings. Front. Med., 8.","DOI":"10.3389\/fmed.2021.809118"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrg3742","article-title":"Engineering adeno-associated viruses for clinical gene therapy","volume":"15","author":"Kotterman","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41587-020-00793-4","article-title":"Deep diversification of an AAV capsid protein by machine learning","volume":"39","author":"Bryant","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of genome size on AAV vector packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ymthe.2017.11.019","article-title":"Triple Vectors Expand AAV Transfer Capacity in the Retina","volume":"26","author":"Maddalena","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41434-020-0174-4","article-title":"Large gene delivery to the retina with AAV vectors: Are we there yet?","volume":"28","author":"Trapani","year":"2021","journal-title":"Gene Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"E8547","DOI":"10.1073\/pnas.1805055115","article-title":"Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector","volume":"115","author":"Cideciyan","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"a041283","DOI":"10.1101\/cshperspect.a041283","article-title":"Gene Therapy for Rhodopsin Mutations","volume":"12","author":"Lewin","year":"2022","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.crvi.2013.12.002","article-title":"Therapeutic strategy for handling inherited retinal degenerations in a gene-independent manner using rod-derived cone viability factors","volume":"337","author":"Leveillard","year":"2014","journal-title":"Comptes Rendus Biol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"John, M.C., Quinn, J., Hu, M.L., Cehajic-Kapetanovic, J., and Xue, K. (2022). Gene-agnostic therapeutic approaches for inherited retinal degenerations. Front. Mol. Neurosci., 15.","DOI":"10.3389\/fnmol.2022.1068185"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e2944","DOI":"10.1002\/jgm.2944","article-title":"Gene therapy for achromatopsia","volume":"19","author":"Michalakis","year":"2017","journal-title":"J. Gene Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaophthalmol.2020.1032","article-title":"Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia: A Nonrandomized Controlled Trial","volume":"138","author":"Fischer","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ymthe.2018.05.025","article-title":"Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I\/IIa Trial by Intravitreal Delivery","volume":"26","author":"Cukras","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/mt.2008.269","article-title":"High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors","volume":"17","author":"Dinculescu","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.oret.2022.06.013","article-title":"Intravitreal Delivery of rAAV2tYF-CB-hRS1 Vector for Gene Augmentation Therapy in Patients with X-Linked Retinoschisis: 1-Year Clinical Results","volume":"6","author":"Pennesi","year":"2022","journal-title":"Ophthalmol. Retin."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2008.107","article-title":"Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results of a phase I trial","volume":"19","author":"Hauswirth","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ophtha.2021.03.031","article-title":"Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years","volume":"128","author":"Maguire","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13023-020-1304-1","article-title":"The effect of human gene therapy for RPE65-associated Leber\u2019s congenital amaurosis on visual function: A systematic review and meta-analysis","volume":"15","author":"Wang","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1038\/s41433-024-03065-6","article-title":"Voretigene neparvovec for inherited retinal dystrophy due to RPE65 mutations: A scoping review of eligibility and treatment challenges from clinical trials to real practice","volume":"38","author":"Testa","year":"2024","journal-title":"Eye"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"102409","DOI":"10.1016\/j.isci.2021.102409","article-title":"Safety and improved efficacy signals following gene therapy in childhood blindness caused by GUCY2D mutations","volume":"24","author":"Jacobson","year":"2021","journal-title":"iScience"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"105274","DOI":"10.1016\/j.isci.2022.105274","article-title":"Night vision restored in days after decades of congenital blindness","volume":"25","author":"Jacobson","year":"2022","journal-title":"iScience"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","article-title":"Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR","volume":"26","author":"Xue","year":"2020","journal-title":"Nat. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/21678707.2018.1444476","article-title":"Gene therapy for the treatment of X-linked retinitis pigmentosa","volume":"6","author":"Nanda","year":"2018","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/81555","article-title":"Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa","volume":"26","author":"Gal","year":"2000","journal-title":"Nat. Genet."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00439-016-1637-y","article-title":"Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: Results of a phase I trial","volume":"135","author":"Ghazi","year":"2016","journal-title":"Hum. Genet."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.exer.2005.06.015","article-title":"Focus on molecules: Cellular retinaldehyde-binding protein (CRALBP)","volume":"81","author":"Saari","year":"2005","journal-title":"Exp. Eye Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1073\/pnas.92.8.3249","article-title":"Mutation spectrum of the gene encoding the beta subunit of rod phosphodiesterase among patients with autosomal recessive retinitis pigmentosa","volume":"92","author":"McLaughlin","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/mt.2016.37","article-title":"AAV-mediated Gene Therapy Halts Retinal Degeneration in PDE6beta-deficient Dogs","volume":"24","author":"Pichard","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41591-018-0295-0","article-title":"Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect","volume":"25","author":"Cideciyan","year":"2019","journal-title":"Nat. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41591-022-01755-w","article-title":"Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10, a phase 1b\/2 trial","volume":"28","author":"Russell","year":"2022","journal-title":"Nat. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1167\/iovs.17-21560","article-title":"Outcome Measures for Clinical Trials of Leber Congenital Amaurosis Caused by the Intronic Mutation in the CEP290 Gene","volume":"58","author":"Jacobson","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1038\/mtna.2016.89","article-title":"Antisense Oligonucleotide-based Splice Correction for USH2A-associated Retinal Degeneration Caused by a Frequent Deep-intronic Mutation","volume":"5","author":"Slijkerman","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.ophtha.2018.04.001","article-title":"Clustered Regularly Interspaced Short Palindromic Repeats-Based Genome Surgery for the Treatment of Autosomal Dominant Retinitis Pigmentosa","volume":"125","author":"Tsai","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/crispr.2017.0009","article-title":"Allele-Specific CRISPR-Cas9 Genome Editing of the Single-Base P23H Mutation for Rhodopsin-Associated Dominant Retinitis Pigmentosa","volume":"1","author":"Li","year":"2018","journal-title":"CRISPR J."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymthe.2016.12.006","article-title":"CRISPR\/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10","volume":"25","author":"Ruan","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature14592","article-title":"Engineered CRISPR-Cas9 nucleases with altered PAM specificities","volume":"523","author":"Kleinstiver","year":"2015","journal-title":"Nature"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature26155","article-title":"Evolved Cas9 variants with broad PAM compatibility and high DNA specificity","volume":"556","author":"Hu","year":"2018","journal-title":"Nature"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Vazquez-Dominguez, I., Garanto, A., and Collin, R.W.J. (2019). Molecular Therapies for Inherited Retinal Diseases-Current Standing, Opportunities and Challenges. Genes, 10.","DOI":"10.3390\/genes10090654"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"eaav3335","DOI":"10.1126\/sciadv.aav3335","article-title":"In vivo genome editing rescues photoreceptor degeneration via a Cas9\/RecA-mediated homology-directed repair pathway","volume":"5","author":"Cai","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Bohrer, L.R., Wiley, L.A., Burnight, E.R., Cooke, J.A., Giacalone, J.C., Anfinson, K.R., Andorf, J.L., Mullins, R.F., Stone, E.M., and Tucker, B.A. (2019). Correction of NR2E3 Associated Enhanced S-cone Syndrome Patient-specific iPSCs using CRISPR-Cas9. Genes, 10.","DOI":"10.3390\/genes10040278"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"eaax1210","DOI":"10.1126\/sciadv.aax1210","article-title":"CRISPR-Cas9-mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis","volume":"5","author":"Jo","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","article-title":"Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10","volume":"25","author":"Maeder","year":"2019","journal-title":"Nat. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene Editing for CEP290-Associated Retinal Degeneration","volume":"390","author":"Pierce","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1089\/hum.2020.231","article-title":"Genome-Editing Strategies for Treating Human Retinal Degenerations","volume":"32","author":"Quinn","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Kantor, A., McClements, M.E., and MacLaren, R.E. (2020). CRISPR-Cas9 DNA Base-Editing and Prime-Editing. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176240"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41596-020-00450-9","article-title":"Precision genome editing using cytosine and adenine base editors in mammalian cells","volume":"16","author":"Huang","year":"2021","journal-title":"Nat. Protoc."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41551-019-0501-5","article-title":"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses","volume":"4","author":"Levy","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1038\/s41467-023-40655-6","article-title":"AAV-mediated base-editing therapy ameliorates the disease phenotypes in a mouse model of retinitis pigmentosa","volume":"14","author":"Wu","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.omtn.2023.02.011","article-title":"In vivo base editing rescues photoreceptors in a mouse model of retinitis pigmentosa","volume":"31","author":"Su","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s41551-022-00911-4","article-title":"Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors","volume":"6","author":"Davis","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ymthe.2021.07.011","article-title":"Dual-AAV delivering split prime editor system for in vivo genome editing","volume":"30","author":"Zhi","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41551-021-00788-9","article-title":"Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases","volume":"6","author":"Jang","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-022-01234-1","article-title":"Dual-AAV split prime editor corrects the mutation and phenotype in mice with inherited retinal degeneration","volume":"8","author":"She","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging Issues in AAV-Mediated In Vivo Gene Therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e171356","DOI":"10.1172\/JCI171356","article-title":"Nonviral base editing of KCNJ13 mutation preserves vision in a model of inherited retinal channelopathy","volume":"133","author":"Kabra","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/s41587-023-02078-y","article-title":"Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo","volume":"42","author":"An","year":"2024","journal-title":"Nat. Biotechnol."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/11\/1356\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:18:34Z","timestamp":1760113114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/11\/1356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":138,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["life14111356"],"URL":"https:\/\/doi.org\/10.3390\/life14111356","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]}}}